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ABSTRACT
Mycoplasma species relevant to the urogenital tract include
mycoplasma hominis, mycoplasma genitalia and ureaplasma
urealyticum. Their occurrence in the context of urogynaeco-
logical disease has been demonstrated in urethritis, cystitis
and upper renal tract infections. Their role in hyperactive
bladder and interstitial cystitis/painful bladder syndrome is
controversial. All the above-mentioned microorganisms can
occur as commensals or as potential pathogens. In most cases
their role in any particular pathology cannot be proven, only
presumed. The aim of this systematic review was to summa-
rise current knowledge on the influence of mycoplasma and
ureaplasma in urogynaecological pathology and to provide
clinical guidance on diagnosis (when and how is pathogen de-
tection indicated?) and treatment. 377 relevant articles were
analysed. In summary: a urethral swab for PCR analysis of the
three bacteria should be performed in the context of sympto-
matic sterile leukocyturia, chronic urethritis and suspected
hyperactive bladder or interstitial cystitis/painful bladder syn-
drome. Symptomatic women should be treated strictly ac-
cording to results of the antibiogram.
ZUSAMMENFASSUNG
Die im Urogenitaltrakt relevanten Mykoplasmen sind Myco-
plasma hominis, Mycoplasma genitalium und Ureaplasma
urealyticum. Ihr Vorkommen wurde bei urogynäkologischen
Krankheiten bereits bei der Urethritis, Zystitis und bei oberen
Harnwegsinfekten erwiesen. Ihre Beteiligung an der Entste-
hung der hyperaktiven Blase sowie der interstitiellen Zystitis/
beim Bladder Pain Syndrome wird kontrovers diskutiert. Alle
genannten Erreger können sowohl als einfache Kommensalen
als auch als potenziell pathogene Keime vorkommen. In den
meisten Fällen kann ihre Verantwortlichkeit für die jeweilige
Pathologie nur vermutet und nicht bewiesen werden. Ziel die-
ses systematischen Reviews ist es, den aktuellen Wissens-
stand zum Einfluss von Mykoplasmen und Ureaplasmen auf
urogynäkologische Pathologien bei Frauen zusammenzufas-
sen und dem Kliniker Anhalt zu geben, wann und wie die Erre-
gersuche indiziert ist und wie die Keime behandelt werden
sollten. 377 gefundene Artikel wurden zu dieser Fragestellung
analysiert. Fazit: Bei steriler symptomatischer Leukozyturie,
chronischer Urethritis sowie bei Verdacht auf hyperaktive Bla-
se oder interstitielle Zystitis/Bladder Pain Syndrome sollte ein
Urethraabstrich mit PCR-Analyse auf die 3 Keime durch-
geführt werden. Die Therapie sollte bei symptomatischen
Frauen nur nach Antibiogramm erfolgen.
GebFra Science | Review
1299Combaz(-Söhnchen) N, Kuhn A. A Systematic Review… Geburtsh Frauenheilk 2017; 77: 1299–1303
GebFra Science | ReviewIntroduction
Mycoplasma and ureaplasma species, which are parasitic to hu-
mans, are the smallest known cell-wall-free intra- and extracellular
bacteria belonging to the class Mollicutes. Their lack of a cell wall,
extremely small genome and limited capacity for biosynthesis to-
gether explain their parasitic or saprophytic life style, their sensi-
tivity to environmental factors, resistance to lactam antibiotics
and high demands on living conditions.
These organisms can cause numerous often chronic conditions
in humans. As parasites or commensals they receive essential me-
tabolites such as fatty acids, amino acids, cholesterol and nucleic
acid precursors from their host. Ureaplasma are defined and dif-
ferentiated from mycoplasma species by their characteristic lysis
of urea. Sixteen of the over 200 mycoplasma species known in
the animal and plant kingdoms occur in the human body, however
only six of these appear to be of pathological importance in im-
munocompetent human beings: mycoplasma pneumoniae, my-
coplasma hominis, mycoplasma genitalium, mycoplasma fermen-
tans, ureaplasma parvum und ureaplasma urealyticum [1]. Only
mycoplasma hominis, mycoplasma genitalium and ureaplasma
urealyticum are important pathogens in the human genital tract.
The prevalence of bacterial colonisation in women has been
shown to correlate with number of sexual partners in previous
months [2], and prevalence differs according to geographic and
socio-economic circumstances. The pathogenic potential of these
organisms is however not nearly as high as other sexually trans-
mitted pathogens (especially chlamydia trachomatis).
Because of the close topographical relationship between the
female urethra and genital tract it can be assumed that bacterial
colonisation of the former from the latter can affect the urinary
tract. A lot is already known about mycoplasma-associated genital
tract infections, however there is still a lack of clarity on the influ-
ence and pathogenic potential of mycoplasma and ureaplasma
species in the context of urinary tract infections and other urogy-
naecological symptoms such as irritable bladder and interstitial
cystitis/bladder pain syndrome.
The aim of this review is to summarise current knowledge on
the prevalence and effects of mycoplasma and ureaplasma infec-
tions, the best methods of pathogen detection and best treat-
ment options for the associated urogynaecological conditions
(upper and lower urinary tract infections, urethritis, overactive
bladder [OAB], interstitial cystitis [IC]/the bladder pain syndrome
[BPS] [3]). The results presented are intended to be a practical
treatment aid for clinicians.Review
Literature search
A systematic literature search was performed in the data banks
PubMed and MEDLINE for publications between 1970 and 2017.
Both “mycoplasma” and “ureaplasma” were used as search terms
coupled with the following: “cystitis, bladder infection, urinary
tract infection, LUTS, lower urinary tract, urethra, urethritis, py-
elonephritis, upper urinary tract infection, immune deficiency,
overactive bladder, hyperactive bladder, bladder irritation, inter-1300 Combazstitial cystitis, chronic pelvic pain, bladder pain, treatment, labora-
tory analyses, detection and analysis”. For overall information on
the topic a further search using the following terms was per-
formed: “sexually transmitted diseases woman, reproductive
tract, infertility, pregnancy, neonatal infection and delivery trans-
mission”. Both authors performed the research independently.
Since very few publications were found on overactive bladder
and interstitial cystitis/the bladder pain syndrome an additional
search was conducted in the databases Scopus, Ovid and Science
Direct. ▶ Table 1 summarises the relevant literature found.
The initial literature analysis yielded 2055 articles. Together
with the extended literature search a total of 2269 articles were
identified. 54 publications were regarded by both authors as rele-
vant and served as the basis for this review (▶ Fig. 1).
Results
The role of mycoplasma and ureaplasma
in urinary tract infections
The persistence of irritable bladder symptoms following a urinary
tract infection is a challenging situation for clinicians. Most uro-
pathogenic organisms – especially those originating from faeces –
can be demonstrated on standard culture. Mycoplasma and urea-
plasma species on the other hand are not. When these organisms
are specifically sought they may be found in both asymptomatic
[4] and symptomatic patients with sterile leukocyturia [5]. In
women pathological significance is differentiated from harmless
colonisation by the presence of clinical symptoms. This is compli-
cated in addition by the fact that bacterial count in urine does not
necessarily correlate with the amount of bacteria in the bladder
wall. A significant number of these intracellular organisms may
occur in the bladder wall in the absence of bacteriuria.
Mycoplasma hominis and ureaplasma urealyticum have also
been demonstrated in patients with pyelonephritis [6]. The path-
ogens are thought to have reached the renal pelvis exclusively by
ascending infection from the lower urinary tract. The detection of
bacteria in catheter urine from the bladder does not therefore
prove bacterial colonisation of the upper urinary tract [7].
We agree with the recommendation by Potts et al. that persis-
tent lower urinary tract infection symptoms or pyelonephritis with
negative standard cultures and nonresponse to routine antibiotics
should prompt an active search for mycoplasma and ureaplasma,
with treatment according to antibiogram if findings are positive.
Pathogen detection should be undertaken before further expen-
sive or invasive diagnostic measures are resorted to [8].
Urethritis
Urethritis due to mycoplasma and ureaplasma infection, so-called
“nonchlamydial nongonococcal urethritis”, is extensively de-
scribed in men. There is however very little data on the topic in
women: Moi et al., Falk et al. and Ross & Jensen have all described
urethritis in women caused by or associated with mycoplasma
genitalium [9–11].
Although mycoplasma hominis and ureaplasma urealyticum
have been found in women with urethritis [12], clear evidence of
causative effect is still lacking. Kyndel et al. recently published a
case-control study on the incidence of mycoplasma genitalium,
ureaplasma urealyticum and ureaplasma parvum in patients with(-Söhnchen) N, Kuhn A. A Systematic Review… Geburtsh Frauenheilk 2017; 77: 1299–1303
▶ Table 1 Search criteria coupled with the terms “mycoplasma”
and “ureaplasma” and articles found. Results are shown for the
systematic literature search in Pubmed and Medline using all rele-
vant search criteria, and in Scopus, Ovid and Science Direct using
search terms “overactive bladder, hyperactive bladder, bladder irri-
tation, interstitial cystitis, chronic pelvic pain and bladder pain”with
specification of subtopics.
Search criteria No. articles found
Cystitis 17
Bladder infection 22
Urinary tract infection 100
LUTS 7
Lower urinary tract 22
Urethra 106
Urethritis 266
Pyelonephritis 14
Upper urinary tract infection 2
Immune deficiency 52
Overactive bladder 8
Hyperactive bladder 3
Bladder irritation 6
Interstitial cystitis 66
Chronic pelvic pain 116
Bladder pain 25
Treatment 483
Laboratory analysis 8
Detection and analysis 7
Sexually transmitted diseases woman 134
Reproduction tract 91
Infertility 178
Pregnancy 403
Neonate infection 123
Delivery transmission 10
Total studies identified
n = 2269
Remaining studies
n = 1339
Remaining studies
n = 679
Total remaining original articles
analysed
n = 377
Publications used for this article
n = 54
Objective exclusion criteria
Subjective exclusion criteria
Double references eliminated
n = 302
Irrelevant
No longer current
Methodology deficient
Language
Review
Studies only on men
Animal studies
In vitro studies
n = 529
n = 12
n = 119
n = 258
n = 247
n = 337
n = 71
n = 17
▶ Fig. 1 Literature search flow diagram. The initial 2269 identified
articles were analysed. Original publications in German, English and
French were included. Using objective and subjective selection cri-
teria all review articles, studies conducted only on men or animals
and in vitro studies were excluded from the analysis. Double refer-
ences and studies regarded as irrelevant were also eliminated. 377
articles remained for final analysis. 54 of these publications were
regarded as currently relevant and served as the basis for this ar-
ticle.chronic urethral pain. In contrast to Stamm et al. [13], the authors
found no difference between affected patients and the control
group [14].
In summary, data on this topic in women is sketchy. In the con-
text of chronic urethral symptoms with negative routine cultures
we recommend a urethral swab with PCR analysis for the three rel-
evant mollicutes, and in case of positive findings appropriate
treatment according to resistogram.
Can mycoplasma and ureaplasma cause overactive bladder
or interstitial cystitis?
The International Continence Society (ICS) defines OAB as urinary
urgency with or without urgency urinary incontinence in associa-
tion with urinary frequency and/or nocturia [15]. The symptoms
thus match those of simple cystitis.
Interstitial cystitis – recently renamed the Bladder Pain Syn-
drome [3] – is defined by “chronic lower abdominal pain (contin-
uous for at least six months) with discomfort or pressure relatedCombaz(-Söhnchen) N, Kuhn A. A Systematic Review… Geburtsh Frauenheilk 2017; 77: 1299–1to the bladder. In addition at least one further symptom is present
such as persistent urinary urgency or frequency” [15].
There is therefore overlap between the symptoms of OAB and
BPS. OAB is more common around menopause whereas BPS
mostly affects premenopausal women. Both OAB [16] and BPS
[17] occur more commonly in women than men. The diagnoses
OAB and IC/BPS can only be made after exclusion of possible in-
fectious and other pathologies. The aetiology of OAB is mostly,
and that of BPS currently still always fully unexplained [18].
The theory that initial injury to the urothelium through acute
or chronic infection, causing persistent irritation of the bladder
wall and subsequently OAB and IC/BPS, has not been proven. Nei-
ther a particular microorganism nor any specific spectrum of
pathogens has been shown to be related to the two conditions.
In the late 1990s, using the laboratory methods of the day var-
ious investigators attempted to ascribe an infectious aetiology to1301303
GebFra Science | Reviewinterstitial cystitis – without success [19,20]. Despite controver-
sial results [21] numerous studies however showed positive out-
comes with empiric antibiotic treatment (doxycycline) for OAB
and IC/BPS [22–25]. The question still remains whether OAB/IC/
BPS can in fact be defined as idiopathic. Chronic infection with
one or more as yet undetected pathogens seems more likely.
Since mycoplasma and ureaplasma species are often eradicated
by doxycycline and are better detected with newer diagnostic
methods, the question must be asked once again whether the
findings from the 1990s are still valid today, and whether there is
in fact a link between OAB/BPS and mollicutes.
Numerous recent studies have shown that ureaplasma and my-
coplasma species can be detected in the urine of women with
OAB [26,27] or IC [25]. Potts et al. showed that symptoms im-
proved in patients with IC following targeted antibiotic treatment
[25]. A thorough search through the current available literature
however brings us to the conclusion that there is far too little data
to provide an evidence-based answer to this question. We there-
fore agree with the recommendation that all patients with chronic
unexplained urinary tract symptoms should be tested for molli-
cutes (mycoplasma and ureaplasma) before invasive diagnostic
measures and long-term treatments. Patients with positive bacte-
rial testing should be treated accordingly.
What are the best detection methods for mycoplasma
and ureaplasma?
Mycoplasma genitalium is not detected on routine culture due to
extremely slow growth. Real-time polymerase chain reaction
(PCR) is the diagnostic method of choice. In contrast, ureaplasma
urealyticum and mycoplasma hominis can be identified on culture
or PCR [28].
It is important for the clinician to know that correct sampling
technique from the appropriate site is at least as important for or-
ganism detection as the choice of laboratory method [29]! Hum-
burg et al. found that detection rates of mycoplasma and urea-
plasma in women with urinary tract symptoms were higher using
urethral swabs than early morning urine cultures or vaginal swabs
[30], however in the presence of vaginal itch vaginal swabs pro-
vided the best results [31]. Freezing of PCR specimens appears to
reduce bacterial detection [32].
Treatment of infections
The most difficult question is left to the clinician, who must de-
cide whether a given bacterium, proven on laboratory tests, is
pathogenically significant or not.
Ureaplasma and mycoplasma species do not have a cell wall.
Beta-lactam antibiotics and vancomycin are thus ineffective. Cy-
clines (doxycycline, monocycline), josamycin and the fluoroqui-
nolones are effective against the three species known to be path-
ogenic in the urogenital tract. Tetracyclines and the fluoroquino-
lones are the first choice antibiotics. In pregnant women in whom
these drugs are contraindicated macrolides such as erythromycin
are often used.
In addition to the naturally occurring resistances there is in-
creasing acquired antibiotic resistance so that if possible treat-
ment should only begin once the results of antibiotic resistance
testing are available.1302 CombazCurrent treatment options include:
▪ azithromycin 1 g as a single dose
▪ azithromycin 1,5 g total dose given over 5 days
▪ or doxycycline 100mg 2× daily for 7 days.
Treatment success should be tested threeweeks after treatment at
the earliest, especially in the case ofmycoplasma genitalium. In the
presence of bacterial persistence common antibiotic regimes are
▪ metronidazole 500mg 2×/day for 5–7 days plus azithromycin
for 5 days
▪ or doxycycline for 7 days
▪ or moxifloxacin 400mg per os 1×/day for 7–14 days [33].
Moxifloxacin should be used with caution and only in the context
of treatment failure since it can cause a rare but severe liver reac-
tion. Mycoplasma genitalium infection acquired in Southeast Asia
is resistant to macrolides and quinolones in 10% of cases and pris-
tinamycin is the only effective antibiotic in these patients [34].
Treatment of the patientʼs partner with the same antibiotic
shown to be effective in the index patient is generally recom-
mended. Condom use or abstinence from sexual intercourse is
recommended until symptoms have resolved.
Outlook for the future
New laboratory methods and gene analyses provide promise for
the future: it has recently become possible to determine the fe-
male microbiome in catheter urine using culture and 16S RNA se-
quencing. This has already led to the finding that urine of symp-
tom-free patients contains bacteria and is not sterile as previously
assumed [35,36]. Urine appears to constitute its own microbio-
logical niche that is extremely diverse andmay include typical uro-
pathogens such as mycoplasma and ureaplasma species [26,36].
Limitations of this review
There is little factual knowledge regarding women in this field. Stud-
iesonmen,whichare farmorenumerous,weredeliberatelyexcluded
fromthis analysis inorder to focusandprovideclarityon theevidence
in women. Preclinical studies would expand on these findings.
The heterogeneity of definitions e.g. interstitial cystitis, the
painful bladder syndrome and OAB is a further limitation since
they were not used according to the international criteria of the
IUGA or ICS in all articles and are thus of limited informative value.
Larger, high evidence level, randomised studies of treatment are
lacking.Conclusion
Our knowledge about mycoplasma and ureaplasma species in the
urogenital tract is incomplete. There is very little literature on this
topic in women. Further studies especially in women are urgently
needed. In view of the current data situation these pathogens,
which are difficult to culture, should be actively sought by urethral
swab for PCR analysis in patients with recurrent infections or when
standard microbiological cultures/swabs are negative. Treatment
of symptomatic women should always be guided by antibiotic re-
sistance testing. It can be presumed that the role of these patho-
gens in women with chronic urinary tract symptoms has been(-Söhnchen) N, Kuhn A. A Systematic Review… Geburtsh Frauenheilk 2017; 77: 1299–1303
underestimated as they are difficult to detect and their intracellu-
lar nature makes conventional antibiotics ineffective.
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